10. Referanser

Abukora, F., Nambirajan, T., Albqami, N., Leeb, K., Jeschke, S., Gschwendtner, M., & Janetschek, G. (2005). Laparoscopic nephron sparing surgery: evolution in a decade. European Urology, 47(4), 488-493; discussion 493. https://doi.org/10.1016/j.eururo.2004.12.021

Ahrar, K., Matin, S., Wood, C. G., Wallace, M. J., Gupta, S., Madoff, D. C., . . . Hicks, M. E. (2005). Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. Journal of Vascular and Interventional Radiology, 16(5), 679-688. https://doi.org/10.1097/01.RVI.0000153589.10908.5F

Al Aynati, M., Chen, V., Salama, S., Shuhaibar, H., Treleaven, D., & Vincic, L. (2003). Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Archives of Pathology and Laboratory Medicine, 127(5), 593-596.

Alamdari, F. I., & Ljungberg, B. (2005). Adrenal metastasis in renal cell carcinoma: a recommendation for adjustment of the TNM staging system. Scandinavian Journal of Urology and Nephrology, 39(4), 277-282. https://doi.org/10.1080/003655905100077775

Atzpodien, J., Schmitt, E., Gertenbach, U., Fornara, P., Heynemann, H., Maskow, A., . . . German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. (2005). Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). British Journal of Cancer, 92(5), 843-846. https://doi.org/10.1038/sj.bjc.6602443

Avery, R. A., Harris, J. E., Davis, C. J., Jr., Borgaonkar, D. S., Byrd, J. C., & Weiss, R. B. (1996). Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer, 78(1), 128-132. https://doi.org/10.1002/(SICI)1097-0142(19960701)78:1<128::AID-CNCR18>3.0.CO;2-1

Baldwin, D. D., Dunbar, J. A., Parekh, D. J., Wells, N., Shuford, M. D., Cookson, M. S., . . . McDougall, E. M. (2003). Single-center comparison of purely laparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. Journal of Endourology, 17(3), 161-167. https://doi.org/10.1089/089277903321618725

Bechtold, R. E., & Zagoria, R. J. (1997). Imaging approach to staging of renal cell carcinoma. Urologic Clinics of North America, 24(3), 507-522. https://doi.org/10.1016/s0094-0143(05)70399-2

Beisland, C., Medby, P. C., & Beisland, H. O. (2002a). Nyrekreft--en retrospektiv undersøkelse av 368 pasienter. Tidsskrift for den Norske Legeforening, 122(25), 2431-2435.

Beisland, C., Medby, P. C., & Beisland, H. O. (2002b). Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scandinavian Journal of Urology and Nephrology, 36(6), 414-418. https://doi.org/10.1080/003655902762467558

Beisland, C., Medby, P. C., & Beisland, H. O. (2004). Presumed radically treated renal cell carcinoma--recurrence of the disease and prognostic factors for subsequent survival. Scandinavian Journal of Urology and Nephrology, 38(4), 299-305. https://doi.org/10.1080/00365590410028818

Beisland, C., Medby, P. C., Sander, S., & Beisland, H. O. (2000). Nephrectomy - indications, complications and postoperative mortality in 646 consecutive patients. European Urology, 37(1), 58-64. https://doi.org/10.1159/000020101

Beitler, J. J., Makara, D., Silverman, P., & Lederman, G. (2004). Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. American Journal of Clinical Oncology, 27(6), 646-648. https://doi.org/10.1097/01.coc.0000145289.57705.07

Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P., & Fleischmann, J. (1995). Cytoreductive surgery for stage IV renal cell carcinoma. Journal of Urology, 154(1), 32-34.

Bensalah, K., Leray, E., Fergelot, P., Rioux-Leclercq, N., Tostain, J., Guille, F., & Patard, J. J. (2006). Prognostic value of thrombocytosis in renal cell carcinoma. Journal of Urology, 175(3 Pt 1), 859-863. https://doi.org/10.1016/S0022-5347(05)00526-4

Bergström, A., Hsieh, C. C., Lindblad, P., Lu, C. M., Cook, N. R., & Wolk, A. (2001). Obesity and renal cell cancer--a quantitative review. British Journal of Cancer, 85(7), 984-990. https://doi.org/10.1054/bjoc.2001.2040

Birkmeyer, J. D., Siewers, A. E., Finlayson, E. V., Stukel, T. A., Lucas, F. L., Batista, I., . . . Wennberg, D. E. (2002). Hospital volume and surgical mortality in the United States. New England Journal of Medicine, 346(15), 1128-1137. https://doi.org/10.1056/NEJMsa012337

Bissada, N. K., Yakout, H. H., Babanouri, A., Elsalamony, T., Fahmy, W., Gunham, M., . . . Chaudhary, U. B. (2003). Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology, 61(1), 89-92. https://doi.org/10.1016/s0090-4295(02)02119-2

Bjørge, T., Tretli, S., & Engeland, A. (2004). Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. American Journal of Epidemiology, 160(12), 1168-1176. https://doi.org/10.1093/aje/

Blacher, E., Johnson, D. E., & Haynie, T. P. (1985). Value of routine radionuclide bone scans in renal cell carcinoma. Urology, 26(5), 432-434. https://doi.org/10.1016/0090-4295(85)90148-7

Blom, J. H. M., van Poppel, H., Marechal, J. M., Jacqmin, D., Sylvester, R., Schroder, F. H., & de Prijck, L. (1999). Radical nephrectomy with and without lymph node dissection: Preliminary results of the EORTC randomized phase III protocol 30881. European Urology, 36(6), 570-575. https://doi.org/10.1159/000020050

Blute, M. L., Leibovich, B. C., Cheville, J. C., Lohse, C. M., & Zincke, H. (2004a). A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. Journal of Urology, 172(2), 465-469. https://doi.org/10.1097/01.ju.0000129815.91927.85

Blute, M. L., Leibovich, B. C., Lohse, C. M., Cheville, J. C., & Zincke, H. (2004b). The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU International, 94(1), 33-41. https://doi.org/10.1111/j.1464-410X.2004.04897.x

Bonsib, S. M. (2004). The renal sinus is the principal invasive pathway - A prospective study of 100 renal cell carcinomas. American Journal of Surgical Pathology, 28(12), 1594-1600. https://doi.org/10.1097/00000478-200412000-00007

Bonsib, S. M., Gibson, D., Mhoon, M., & Greene, G. F. (2000). Renal sinus involvement in renal cell carcinomas. American Journal of Surgical Pathology, 24(3), 451-458. https://doi.org/10.1097/00000478-200003000-00015

Bos, S. D., Piers, D. A., & Mensink, H. J. (1995). Routine bone scan and serum alkaline phosphatase for staging in patients with renal cell carcinoma is not cost-effective. European Journal of Cancer, 31a(13-14), 2422-2423. https://doi.org/10.1016/0959-8049(95)00412-2

Bostad, L. (red.). (2001). Veileder i biopsibesvarelse av maligne svulster. Oslo: Den Norske lægeforening.

Bray, F. (red.). (2004). Cancer in Norway 2001: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway.

Bretheau, D., Lechevallier, E., de Fromont, M., Sault, M. C., Rampal, M., & Coulange, C. (1995). Prognostic value of nuclear grade of renal cell carcinoma. Cancer, 76(12), 2543-2549. https://doi.org/10.1002/1097-0142(19951215)76:12<2543::aid-cncr2820761221>3.0.co;2-s

Brierly, R. D., Thomas, P. J., Harrison, N. W., Fletcher, M. S., Nawrocki, J. D., & Ashton-Key, M. (2000). Evaluation of fine-needle aspiration cytology for renal masses. BJU International, 85(1), 14-18. https://doi.org/10.1046/j.1464-410x.2000.00417.x

Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., Vaishampayan, U., . . . McDermott, D. (2007). Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. Journal of Clinical Oncology, 25(29), 4536-4541. https://doi.org/10.1200/JCO.2007.11.5154

Cannady, S. B., Cavanaugh, K. A., Lee, S. Y., Bukowski, R. M., Olencki, T. E., Stevens, G. H., . . . Suh, J. H. (2004). Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. International Journal of Radiation Oncology, Biology, Physics, 58(1), 253-258. https://doi.org/10.1016/s0360-3016(03)00818-6

Carmignani, G., Traverso, P., & Corbu, C. (2001). Incidental splenectomy during left radical nephrectomy: reasons and ways to avoid it. Urologia Internationalis, 67(3), 195-198. https://doi.org/10.1159/000050986

Chao, D., Zisman, A., Pantuck, A. J., Gitlitz, B. J., Freedland, S. J., Said, J. W., . . . Belldegrun, A. S. (2002). Collecting duct renal cell carcinoma: clinical study of a rare tumor. Journal of Urology, 167(1), 71-74. https://doi.org/10.1016/s0022-5347(05)65385-2

Chauveau, D., Duvic, C., Chretien, Y., Paraf, F., Droz, D., Melki, P., . . . Grunfeld, J. P. (1996). Renal involvement in von Hippel-Lindau disease. Kidney International, 50(3), 944-951. https://doi.org/10.1038/ki.1996.395

Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003). Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. American Journal of Surgical Pathology, 27(5), 612-624. https://doi.org/10.1097/00000478-200305000-00005

Chiu, B. C., Lynch, C. F., Cerhan, J. R., & Cantor, K. P. (2001). Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa. Annals of Epidemiology, 11(1), 28-37. https://doi.org/10.1016/s1047-2797(00)00175-7

Chow, W. H., Devesa, S. S., Warren, J. L., & Fraumeni, J. F., Jr. (1999). Rising incidence of renal cell cancer in the United States. JAMA, 281(17), 1628-1631. https://doi.org/10.1001/jama.281.17.1628

Citterio, G., Bertuzzi, A., Tresoldi, M., Galli, L., Di Lucca, G., Scaglietti, U., & Rugarli, C. (1997). Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. European Urology, 31(3), 286-291. https://doi.org/10.1159/000474469

Clark, J. I., Atkins, M. B., Urba, W. J., Creech, S., Figlin, R. A., Dutcher, J. P., . . . Margolin, K. A. (2003). Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. Journal of Clinical Oncology, 21(16), 3133-3140. https://doi.org/10.1200/JCO.2003.02.014

Coll, D. M., Uzzo, R. G., Herts, B. R., Davros, W. J., Wirth, S. L., & Novick, A. C. (1999). 3-dimensional volume rendered computerized tomography for preoperative evaluation and intraoperative treatment of patients undergoing nephron sparing surgery. Journal of Urology, 161(4), 1097-1102.

Cooper, C. S., Cohen, M. B., & Donovan, J. F., Jr. (1996). Splenectomy complicating left nephrectomy. Journal of Urology, 155(1), 30-36.

Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A., & Wilt, T. (2005). Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews, (1), CD001425. https://doi.org/10.1002/14651858.CD001425.pub2

Dechet, C. B., Sebo, T., Farrow, G., Blute, M. L., Engen, D. E., & Zincke, H. (1999). Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. Journal of Urology, 162(4), 1282-1284; discussion 1284-1285.

Delahunt, B., Eble, J. N., McCredie, M. R., Bethwaite, P. B., Stewart, J. H., & Bilous, A. M. (2001). Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Human Pathology, 32(6), 590-595. https://doi.org/10.1053/hupa.2001.24984

Desai, M. M., Gill, I. S., Ramani, A. P., Matin, S. F., Kaouk, J. H., & Campero, J. M. (2003). Laparoscopic radical nephrectomy for cancer with level I renal vein involvement. Journal of Urology, 169(2), 487-491. https://doi.org/10.1097/01.ju.0000041955.93458.f5

Donskov, F. (2007). Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Danish Medical Bulletin, 54(4), 249-265.

Dudek, A. Z., Zolnierek, J., Dham, A., Lindgren, B. R., & Szczylik, C. (2009). Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer, 115(1), 61-67. https://doi.org/10.1002/cncr.24009

Dunn, M. D., Portis, A. J., Shalhav, A. L., Elbahnasy, A. M., Heidorn, C., McDougall, E. M., & Clayman, R. V. (2000). Laparoscopic versus open radical nephrectomy: a 9-year experience. Journal of Urology, 164(4), 1153-1159.

Eble, J. N., Sauter, G., Epstein, J. I., & Sesserhenn, I. A. (red.). (2004). Pathology an genetics of tumours of the urinary system and male genital organs (World Health Organization Classification of Tumours). Lyon: IARCpress.

Edna, T. H., Vada, K., Hesselberg, F., & Mjølnerød, O. K. (1992). Blood transfusion and survival following surgery for renal carcinoma. British Journal of Urology, 70(2), 135-138. https://doi.org/10.1111/j.1464-410x.1992.tb15690.x

Eggener, S. E., Yossepowitch, O., Pettus, J. A., Snyder, M. E., Motzer, R. J., & Russo, P. (2006). Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. Journal of Clinical Oncology, 24(19), 3101-3106. https://doi.org/10.1200/JCO.2005.04.8280

Elmore, J. M., Kadesky, K. T., Koeneman, K. S., & Sagalowsky, A. I. (2003). Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer, 98(11), 2329-2334. https://doi.org/10.1002/cncr.11806

Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., . . . Target Study Group. (2007a). Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine, 356(2), 125-134. https://doi.org/10.1056/NEJMoa060655

Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., . . . Bukowski, R. M. (2009a). Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology, 27(20), 3312-3318. https://doi.org/10.1200/JCO.2008.19.5511

Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., . . . Avoren Trial investigators. (2007b). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370(9605), 2103-2111. https://doi.org/10.1016/S0140-6736(07)61904-7

Escudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., . . . Bukowski, R. M. (2009b). Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 27(8), 1280-1289. https://doi.org/10.1200/JCO.2008.19.3342

Escudier, B. J., Bellmunt, J., Negrier, S., Melichar, B., Bracarda, S., Ravaud, A., . . . Jethwa, S. (2009c). Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 27(15S), 5020.

Ficarra, V., Novara, G., Galfano, A., Novella, G., Schiavone, D., & Artibani, W. (2004). Application of tnm, 2002 version, in localized renal cell carcinoma: Is it able to predict different cancer-specific survival probability? Urology, 63(6), 1050-1054.

Ficarra, V., Righetti, R., D'Amico, A., Rubilotta, E., Novella, G., Malossini, G., & Mobilio, G. (2001a). Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology, 61(1), 10-15.

Ficarra, V., Righetti, R., Martignoni, G., D'Amico, A., Pilloni, S., Rubilotta, E., . . . Mobilio, G. (2001b). Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urologia Internationalis, 67(2), 130-134. https://doi.org/10.1159/000050968

Ficarra, V., Schips, L., Guille, F., Li, G., De La Taille, A., Prayer Galetti, T., . . . Patard, J. J. (2005). Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer, 104(5), 968-974. https://doi.org/10.1002/cncr.21254

Figlin, R. A., Thompson, J. A., Bukowski, R. M., Vogelzang, N. J., Novick, A. C., Lange, P., . . . Belldegrun, A. S. (1999). Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. Journal of Clinical Oncology, 17(8), 2521-2529. https://doi.org/10.1200/JCO.1999.17.8.2521

Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., . . . Crawford, E. D. (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine, 345(23), 1655-1659. https://doi.org/10.1056/NEJMoa003013

Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). (2000). FOR-2000-12-01-1208. Hentet fra https://lovdata.no/dokument/SF/forskrift/2000-12-01-1208

Fossa, S. D., Aass, N., Tveter, K., & Dahl, O. (2000). Behandling av nyrekreft med fjernmetastaser. Tidsskrift for den Norske Legeforening, 120(19), 2274-2278.

Frank, I., Blute, M. L., Cheville, J. C., Lohse, C. M., Weaver, A. L., & Zincke, H. (2002). An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. Journal of Urology, 168(6), 2395-2400. https://doi.org/10.1097/01.ju.0000035885.91935.d5

Frank, I., Blute, M. L., Leibovich, B. C., Cheville, J. C., Lohse, C. M., & Zincke, H. (2005). Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. Journal of Urology, 173(6), 1889-1892. https://doi.org/10.1097/01.ju.0000158043.94525.d6

Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. American Journal of Surgical Pathology, 6(7), 655-663. https://doi.org/10.1097/00000478-198210000-00007

Furge, K. A., Lucas, K. A., Takahashi, M., Sugimura, J., Kort, E. J., Kanayama, H. O., . . . Teh, B. T. (2004). Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Research, 64(12), 4117-4121. https://doi.org/10.1158/0008-5472.CAN-04-0534

Galligioni, E., Quaia, M., Merlo, A., Carbone, A., Spada, A., Favaro, D., . . . Talamini, R. (1996). Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer, 77(12), 2560-2566. https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P

Gervais, D. A., McGovern, F. J., Arellano, R. S., McDougal, W. S., & Mueller, P. R. (2003). Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology, 226(2), 417-424. https://doi.org/10.1148/radiol.2262012062

Gettman, M. T., Blute, M. L., Spotts, B., Bryant, S. C., & Zincke, H. (2001). Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer, 91(2), 354-361. https://doi.org/10.1002/1097-0142(20010115)91:2<354::aid-cncr1009>3.0.co;2-9

Gill, I. S., Desai, M. M., Kaouk, J. H., Meraney, A. M., Murphy, D. P., Sung, G. T., & Novick, A. C. (2002). Laparoscopic partial nephrectomy for renal tumor: duplicating open surgical techniques. Journal of Urology, 167(2 Pt 1), 469-467; discussion 475-466.

Gill, I. S., Remer, E. M., Hasan, W. A., Strzempkowski, B., Spaliviero, M., Steinberg, A. P., . . . Novick, A. C. (2005). Renal cryoablation: Outcome at 3 years. Journal of Urology, 173(6), 1903-1907. https://doi.org/10.1097/01.ju.0000158154.28845.c9

Glazer, A. A., & Novick, A. C. (1996). Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. Journal of Urology, 155(2), 448-450. https://doi.org/10.1016/S0022-5347(01)66415-2

Goel, A., Hemal, A. K., & Gupta, N. P. (2002). Retroperitoneal laparoscopic radical nephrectomy and nephroureterectomy and comparison with open surgery. World Journal of Urology, 20(4), 219-223. https://doi.org/10.1007/s00345-002-0263-6

Gore, M. E., Griffin, C. L., Hancock, B., Patel, P. M., Pyle, L., Aitchison, M., . . . Mulders, P. F. (2010). Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet, 375(9715), 641-648. https://doi.org/10.1016/S0140-6736(09)61921-8

Gudbjartsson, T., Einarsson, G. V., & Magnússon, J. (1996). A population-based analysis of survival and incidental diagnosing of renal cell carcinoma patients in Iceland, 1971-1990. Scandinavian Journal of Urology and Nephrology, 30(6), 451-455. https://doi.org/10.3109/00365599609182322

Hafez, K. S., Fergany, A. F., & Novick, A. C. (1999). Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. Journal of Urology, 162(6), 1930-1933. https://doi.org/10.1016/s0022-5347(05)68071-8

Han, K. R., Bui, M. H., Pantuck, A. J., Freitas, D. G., Leibovich, B. C., Dorey, F. J., . . . Belldegrun, A. S. (2003). TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. Journal of Urology, 169(3), 899-903.

Han, K. R., Kim, H. L., Pantuck, A. J., Dorey, F. J., Figlin, R. A., & Belldegrun, A. S. (2004). Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology, 63(5), 841-846. https://doi.org/10.1016/j.urology.2003.12.048

Hayakawa, M., Nakajima, F., Higa, I., Koyama, Y., Hatano, T., & Osawa, A. (1995). [Study on clinical courses of 7 patients undergone resection of adjacent organs in the treatment of locally extensive renal cell carcinoma]. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology, 86(7), 1302-1305. https://doi.org/10.5980/jpnjurol1989.86.1302

Heidenreich, A., & Ravery, V. (2004). Preoperative imaging in renal cell cancer. World Journal of Urology, 22(5), 307-315. https://doi.org/10.1007/s00345-004-0411-2

Henriksson, C., Haraldsson, G., Aldenborg, F., Lindberg, S., & Pettersson, S. (1992). Skeletal Metastases in 102 Patients Evaluated before Surgery for Renal-Cell Carcinoma. Scandinavian Journal of Urology and Nephrology, 26(4), 363-366. https://doi.org/10.3109/00365599209181227

Herts, B. R., Coll, D. M., Lieber, M. L., Streem, S. B., & Novick, A. C. (1999). Triphasic helical CT of the kidneys: Contribution of vascular phase scanning in patients before urologic surgery. American Journal of Roentgenology, 173(5), 1273-1277. https://doi.org/10.2214/ajr.173.5.10541104

Homma, Y., Kawabe, K., Kitamura, T., Nishimura, Y., Shinohara, M., Kondo, Y., . . . Asakage, Y. (1995). Increased incidental detection and reduced mortality in renal cancer--recent retrospective analysis at eight institutions. International Journal of Urology, 2(2), 77-80. https://doi.org/10.1111/j.1442-2042.1995.tb00428.x

Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., . . . Motzer, R. J. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356(22), 2271-2281.

Haas, N., Manola, J., Pins, M., Liu, G., McDermott, D., Nanus, D., . . . Dutcher, J. (2009). ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. Journal of Clinical Oncology, 27(15), 5038.

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2004). Tobacco Smoke and Involuntary Smoking (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 83). Lyon: IARC. Hentet fra https://monographs.iarc.fr/wp-content/uploads/2018/06/mono83.pdf

Ishikura, K., Yoshida, N., Hasegawa, M., Nomura, K., Okamoto, T., Tanji, S., . . . Kubo, T. (1994). [Clinical study of renal cell carcinoma invading adjacent organs]. Hinyokika Kiyo. Acta Urologica Japonica, 40(5), 373-377.

Javidan, J., Stricker, H. J., Tamboli, P., Amin, M. B., Peabody, J. O., Deshpande, A., . . . Amin, M. B. (1999). Prognostic significance of the 1997 TNM classification of renal cell carcinoma. Journal of Urology, 162(4), 1277-1281.

Jayson, M., & Sanders, H. (1998). Increased incidence of serendipitously discovered renal cell carcinoma. Urology, 51(2), 203-205. https://doi.org/10.1016/s0090-4295(97)00506-2

Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., . . . Doehn, C. (2004). Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet, 363(9409), 594-599. https://doi.org/10.1016/S0140-6736(04)15590-6

Johnson, D. B., Solomon, S. B., Su, L. M., Matsumoto, E. D., Kavoussi, L. R., Nakada, S. Y., . . . Cadeddu, J. A. (2004). Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. Journal of Urology, 172(3), 874-877. https://doi.org/10.1097/01.ju.0000135833.67906.ec

Jonasch, E., Wood, C. G., Matin, S. F., Tu, S. M., Pagliaro, L. C., Corn, P. G., . . . Tannir, N. (2009). Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 27(25), 4076-4081. https://doi.org/10.1200/JCO.2008.21.3660

Joslyn, S. A., Sirintrapun, S. J., & Konety, B. R. (2005). Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology, 65(4), 675-680. https://doi.org/10.1016/j.urology.2004.10.068

Juusela, H., Malmio, K., Alfthan, O., & Oravisto, K. J. (1977). Preoperative irradiation in the treatment of renal adenocarcinoma. Scandinavian Journal of Urology and Nephrology, 11(3), 277-281. https://doi.org/10.3109/00365597709179965

Kasibhatla, M., Steinberg, P., Meyer, J., Ernstoff, M. S., & George, D. J. (2007). Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clinical Genitourinary Cancer, 5(4), 291-294. https://doi.org/10.3816/CGC.2007.n.007

Kato, M., Suzuki, T., Suzuki, Y., Terasawa, Y., Sasano, H., & Arai, Y. (2004). Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. Journal of Urology, 172(3), 863-866. https://doi.org/10.1097/01.ju.0000136315.80057.99

Kattan, M. W., Reuter, V., Motzer, R. J., Katz, J., & Russo, P. (2001). A postoperative prognostic nomogram for renal cell carcinoma. Journal of Urology, 166(1), 63-67.

Kavolius, J. P., Mastorakos, D. P., Pavlovich, C., Russo, P., Burt, M. E., & Brady, M. S. (1998). Resection of metastatic renal cell carcinoma. Journal of Clinical Oncology, 16(6), 2261-2266. https://doi.org/10.1200/JCO.1998.16.6.2261

Kennedy, S. M., Merino, M. J., Linehan, W. M., Roberts, J. R., Robertson, C. N., & Neumann, R. D. (1990). Collecting duct carcinoma of the kidney. Human Pathology, 21(4), 449-456. https://doi.org/10.1016/0046-8177(90)90209-n

Kim, H. L., Belldegrun, A. S., Freitas, D. G., Bui, M. H., Han, K. R., Dorey, F. J., & Figlin, R. A. (2003). Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. Journal of Urology, 170(5), 1742-1746. https://doi.org/10.1097/01.ju.0000092764.81308.6a

Kim, H. L., Han, K. R., Zisman, A., Figlin, R. A., & Belldegrun, A. S. (2004). Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. Journal of Urology, 171(5), 1810-1813. https://doi.org/10.1097/01.ju.0000121440.82581.d3

Kjaer, M., Iversen, P., Hvidt, V., Bruun, E., Skaarup, P., Bech Hansen, J., & Frederiksen, P. L. (1987). A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scandinavian Journal of Urology and Nephrology, 21(4), 285-289. https://doi.org/10.3109/00365598709180784

Koga, S., Tsuda, S., Nishikido, M., Ogawa, Y., Hayashi, K., Hayashi, T., & Kanetake, H. (2001). The diagnostic value of bone scan in patients with renal cell carcinoma. Journal of Urology, 166(6), 2126-2128.

Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., . . . Zbar, B. (1997). The Heidelberg classification of renal cell tumours. Journal of Pathology, 183(2), 131-133. https://doi.org/10.1002/(sici)1096-9896(199710)183:2<131::Aid-path931>3.0.Co;2-g

Kozlowski, J. M. (1994). Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urologic Clinics of North America, 21(4), 601-624.

Kuczyk, M., Wegener, G., & Jonas, U. (2005). The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. European Urology, 48(2), 252-257. https://doi.org/10.1016/j.eururo.2005.04.004

Kural, A. R., Demirkesen, O., Onal, B., Obek, C., Tunc, B., Onder, A. U., . . . Solok, V. (2003). Outcome of nephron-sparing surgery: elective versus imperative indications. Urologia Internationalis, 71(2), 190-196. https://doi.org/10.1159/000071845

Lam, J. S., Shvarts, O., Leppert, J. T., Pantuck, A. J., Figlin, R. A., & Belldegrun, A. S. (2005). Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. Journal of Urology, 174(2), 466-472; discussion 472; quiz 801. https://doi.org/10.1097/01.ju.0000165572.38887.da

Lang, H., Lindner, W., de Fromont, M., Molinie, V., Letourneux, H., Meyer, N., . . . Jacqmin, D. (2005). Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma - Assessment of 241 patients with > 15-year follow-up. Cancer, 103(3), 625-629. https://doi.org/10.1002/cncr.20812

Lau, W. K., Blute, M. L., Weaver, A. L., Torres, V. E., & Zincke, H. (2000). Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clinic Proceedings, 75(12), 1236-1242. https://doi.org/10.4065/75.12.1236

Lee, C. T., Katz, J., Fearn, P. A., & Russo, P. (2002). Mode of presentation of renal cell carcinoma provides prognostic information. Urologic Oncology, 7(4), 135-140. https://doi.org/10.1016/s1078-1439(01)00185-5

Lee, C. T., Katz, J., Shi, W., Thaler, H. T., Reuter, V. E., & Russo, P. (2000). Surgical management of renal tumors 4 cm. or less in a contemporary cohort. Journal of Urology, 163(3), 730-736.

Lee, J., Hodgson, D., Chow, E., Bezjak, A., Catton, P., Tsuji, D., . . . Gospodarowicz, M. K. (2005). A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer, 104(9), 1894-1900. https://doi.org/10.1002/cncr.21410

Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., . . . Zincke, H. (2003a). Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer, 97(7), 1663-1671. https://doi.org/10.1002/cncr.11234

Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Weaver, A. L., & Zincke, H. (2004). Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. Journal of Urology, 171(3), 1066-1070. https://doi.org/10.1097/01.ju.0000113274.40885.db

Leibovich, B. C., Han, K. R., Bui, M. H., Pantuck, A. J., Dorey, F. J., Figlin, R. A., & Belldegrun, A. (2003b). Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer, 98(12), 2566-2575. https://doi.org/10.1002/cncr.11851

Levy, D. A., Slaton, J. W., Swanson, D. A., & Dinney, C. P. (1998). Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. Journal of Urology, 159(4), 1163-1167.

Li, G. R., Soulie, M., Escourrou, G., Plante, P., & Pontonnier, F. (1996). Micrometastatic adrenal invasion by renal carcinoma in patients undergoing nephrectomy. British Journal of Urology, 78(6), 826-828. https://doi.org/10.1046/j.1464-410x.1996.02633.x

Lim, D. J., & Carter, M. F. (1993). Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. Journal of Urology, 150(4), 1112-1114. https://doi.org/10.1016/s0022-5347(17)35700-2

Lindblad, P. (2004). Epidemiology of renal cell carcinoma. Scandinavian Journal of Surgery, 93(2), 88-96. https://doi.org/10.1177/145749690409300202

Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., . . . Neckers, L. (2004). Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clinical Cancer Research, 10(18 Pt 2), 6282S-6289S. https://doi.org/10.1158/1078-0432.CCR-050013

Ljungberg, B. (2004). Nephron-sparing surgery--strategies for partial nephrectomy in renal cell carcinoma. Scandinavian Journal of Surgery, 93(2), 126-131. https://doi.org/10.1177/145749690409300207

Ljungberg, B., Alamdari, F. I., Holmberg, G., Granfors, T., & Duchek, M. (1998). Radical nephrectomy is still preferable in the treatment of localized renal cell carcinoma. A long-term follow-up study. European Urology, 33(1), 79-85. https://doi.org/10.1159/000019515

Ljungberg, B., Alamdari, F. I., Rasmuson, T., & Roos, G. (1999). Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU International, 84(4), 405-411. https://doi.org/10.1046/j.1464-410x.1999.00202.x

Ljungberg, B., Hanbury, D. C., Kuczyk, M. A., Merseburger, A. S., Mulders, P. F. A., Patard, J. J., & Sinecu, I. C. (red.). (2007). Guidelines on Renal Cell Carcinoma. Arnhem: European Association of Urology.

Ljungberg, B., Landberg, G., & Alamdari, F. I. (2000). Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scandinavian Journal of Urology and Nephrology, 34(4), 246-251. https://doi.org/10.1080/003655900750041979

Ljungberg, B., Stenling, R., Osterdahl, B., Farrelly, E., Aberg, T., & Roos, G. (1995). Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. Journal of Urology, 154(5), 1681-1684. https://doi.org/10.1016/s0022-5347(01)66749-1

Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). (1999). LOV-1999-07-02-63. Hentet fra https://lovdata.no/dokument/NL/lov/1999-07-02-63

Lundstam, S., Jonsson, O., Lyrdal, D., Peeker, R., & Pettersson, S. (2003). Nephron-sparing surgery for renal cell carcinoma--long-term results. Scandinavian Journal of Urology and Nephrology, 37(4), 299-304. https://doi.org/10.1080/00365590310001647

MacLennan, G. T., Farrow, G. M., & Bostwick, D. G. (1997). Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology, 50(5), 679-684. https://doi.org/10.1016/S0090-4295(97)00335-X

Maisonneuve, P., Agodoa, L., Gellert, R., Stewart, J. H., Buccianti, G., Lowenfels, A. B., . . . Boyle, P. (1999). Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet, 354(9173), 93-99. https://doi.org/10.1016/s0140-6736(99)06154-1

Makhoul, B., De La Taille, A., Vordos, D., Salomon, L., Sebe, P., Audet, J. F., . . . Abbou, C. C. (2004). Laparoscopic radical nephrectomy for T1 renal cancer: the gold standard? A comparison of laparoscopic vs open nephrectomy. BJU International, 93(1), 67-70. https://doi.org/10.1111/j.1464-410x.2004.04558.x

Marshall, M. E., Pearson, T., Simpson, W., Butler, K., & McRoberts, W. (1990). Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. Urology, 36(4), 300-302. https://doi.org/10.1016/0090-4295(90)80232-c

McDermott, D. F., Ghebremichael, M., Signoretti, S., Margolin, K. A., Clark, J., Sosman, J. A., . . . Atkins, M. B. (2010). The high-dose aldesleukin (HD IL-2) Select trial in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 28(15 SUPPL. 1).

McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., . . . Atkins, M. B. (2005). Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 23(1), 133-141. https://doi.org/10.1200/JCO.2005.03.206

McKiernan, J., Yossepowitch, O., Kattan, M. W., Simmons, R., Motzer, R. J., Reuter, V. E., & Russo, P. (2002). Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology, 60(6), 1003-1009. https://doi.org/10.1016/s0090-4295(02)01967-2

Mclaughlin, J. K., Lindblad, P., Mellemgaard, A., Mccredie, M., Mandel, J. S., Schlehofer, B., . . . Adami, H. O. (1995). International Renal-Cell Cancer Study .1. Tobacco Use. International Journal of Cancer, 60(2), 194-198. https://doi.org/10.1002/ijc.2910600211

McNichols, D. W., Segura, J. W., & DeWeerd, J. H. (1981). Renal cell carcinoma: long-term survival and late recurrence. Journal of Urology, 126(1), 17-23. https://doi.org/10.1016/s0022-5347(17)54359-1

Mejean, A., Vogt, B., Cazin, S., Balian, C., Poisson, J. F., & Dufour, B. (2002). Nephron sparing surgery for renal cell carcinoma using selective renal parenchymal clamping. Journal of Urology, 167(1), 234-235.

Mejean, A., Vogt, B., Quazza, J. E., Chretien, Y., & Dufour, B. (1999). Mortality and morbidity after nephrectomy for renal cell carcinoma using a transperitoneal anterior subcostal incision. European Urology, 36(4), 298-302. https://doi.org/10.1159/000020008

Mickisch, G., Carballido, J., Hellsten, S., Schulze, H., & Mensink, H. (2001a). Guidelines on renal cell cancer. European Urology, 40(3), 252-255. https://doi.org/10.1159/000049783

Mickisch, G. H., Garin, A., van Poppel, H., de Prijck, L., Sylvester, R., & European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. (2001b). Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358(9286), 966-970. https://doi.org/10.1016/s0140-6736(01)06103-7

Minervini, A., Lilas, L., Morelli, G., Traversi, C., Battaglia, S., Cristofani, R., & Minervini, R. (2001). Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU International, 88(3), 169-172. https://doi.org/10.1046/j.1464-410x.2001.02315.x

Mitchell, R. E., Gilbert, S. M., Murphy, A. M., Olsson, C. A., Benson, M. C., & McKiernan, J. M. (2006). Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology, 67(2), 260-264. https://doi.org/10.1016/j.urology.2005.08.057

Miyake, H., Haraguchi, T., Takenaka, A., & Fujisawa, M. (2011). Metastatic collecting duct carcinoma of the kidney responded to sunitinib. International Journal of Clinical Oncology, 16(2), 153-155. https://doi.org/10.1007/s10147-010-0116-z

Moch, H., Gasser, T., Amin, M. B., Torhorst, J., Sauter, G., & Mihatsch, M. J. (2000). Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer, 89(3), 604-614.

Motzer, R. J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., & Reuter, V. (2002a). Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. Journal of Clinical Oncology, 20(9), 2376-2381. https://doi.org/10.1200/JCO.2002.11.123

Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002b). Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology, 20(1), 289-296. https://doi.org/10.1200/Jco.2002.20.1.289

Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004). Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 22(3), 454-463. https://doi.org/10.1200/JCO.2004.06.132

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., . . . Record- Study Group. (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer, 116(18), 4256-4265. https://doi.org/10.1002/cncr.25219

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., . . . Record- Study Group. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372(9637), 449-456. https://doi.org/10.1016/S0140-6736(08)61039-9

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., . . . Figlin, R. A. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 27(22), 3584-3590. https://doi.org/10.1200/Jco.2008.20.1293

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., . . . Figlin, R. A. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine, 356(2), 115-124. https://doi.org/10.1056/NEJMoa065044

Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 17(8), 2530-2540. https://doi.org/10.1200/JCO.1999.17.8.2530

Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., . . . Rini, B. I. (2006a). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24(1), 16-24. https://doi.org/10.1200/JCO.2005.02.2574

Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., . . . Michaelson, M. D. (2006b). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295(21), 2516-2524. https://doi.org/10.1001/jama.295.21.2516

Motzer, R. J., & Russo, P. (2000). Systemic therapy for renal cell carcinoma. Journal of Urology, 163(2), 408-417.

Munro, N. P., Woodhams, S., Nawrocki, J. D., Fletcher, M. S., & Thomas, P. J. (2003). The role of transarterial embolization in the treatment of renal cell carcinoma. BJU International, 92(3), 240-244. https://doi.org/10.1046/j.1464-410x.2003.04314.x

Nanus, D. M., Garino, A., Milowsky, M. I., Larkin, M., & Dutcher, J. P. (2004). Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer, 101(7), 1545-1551. https://doi.org/10.1002/cncr.20541

Nasjonal helseplan (2007-2010). (2006). (Særtrykk av St.prp. nr. 1 (2006–2007). Oslo: Helse- og omsorgsdepartementet. Hentet fra http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf

Nesbitt, J. C., Soltero, E. R., Dinney, C. P., Walsh, G. L., Schrump, D. S., Swanson, D. A., . . . Putnam, J. B., Jr. (1997). Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Annals of Thoracic Surgery, 63(6), 1592-1600. https://doi.org/10.1016/s0003-4975(97)00329-9

NICE. (2011). Everolimus for the second-line treatment of advanced renal cell carcinoma (NICE technology appraisal guidance 219). London: National Institute for Health and Clinical Excellence.

Novick, A. C. (2002). Nephron-sparing surgery for renal cell carcinoma. Annual Review of Medicine, 53, 393-407. https://doi.org/10.1146/annurev.med.53.082901.103937

Novick, A. C. (2004). Laparoscopic and partial nephrectomy. Clinical Cancer Research, 10(18 Pt 2), 6322s-6327s. https://doi.org/10.1158/1078-0432.Ccr-050003

Nurmi, M. J., Puntala, P. V., Tyrkkö, J. E., & Antila, L. E. (1985). Transabdominal and lumbar nephrectomy for renal adenocarcinoma. Scandinavian Journal of Urology and Nephrology, 19(2), 129-131. https://doi.org/10.3109/00365598509180240

Nuttall, M., Cathcart, P., van der Meulen, J., Gillatt, D., McIntosh, G., & Emberton, M. (2005). A description of radical nephrectomy practice and outcomes in England: 1995-2002. BJU International, 96(1), 58-61. https://doi.org/10.1111/j.1464-410X.2005.05567.x

O'Brien, W. M., & Lynch, J. H. (1987). Adrenal metastases by renal cell carcinoma. Incidence at nephrectomy. Urology, 29(6), 605-607.

Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5(6), 649-655.

Ono, Y., Hattori, R., Gotoh, M., Yoshino, Y., Yoshikawa, Y., & Kamihira, O. (2005). Laparoscopic radical nephrectomy for renal cell carcinoma: the standard of care already? Current opinion in urology, 15(2), 75-78. https://doi.org/10.1097/01.mou.0000160619.28613.3c

Ono, Y., Kinukawa, T., Hattori, R., Gotoh, M., Kamihira, O., & Ohshima, S. (2001). The long-term outcome of laparoscopic radical nephrectomy for small renal cell carcinoma. Journal of Urology, 165(6 Pt 1), 1867-1870. https://doi.org/10.1097/00005392-200106000-00006

Oudard, S., Banu, E., Vieillefond, A., Fournier, L., Priou, F., Medioni, J., . . . Getug (Groupe d'Etudes des Tumeurs Uro-Génitales). (2007). Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. Journal of Urology, 177(5), 1698-1702. https://doi.org/10.1016/j.juro.2007.01.063

Palapattu, G. S., Pantuck, A. J., Dorey, F., Said, J. W., Figlin, R. A., & Belldegrun, A. S. (2003). Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. Journal of Urology, 170(3), 768-772; discussion 772. https://doi.org/10.1097/01.ju.0000082580.13597.a2

Pantuck, A. J., Zisman, A., Dorey, F., Chao, D. H., Han, K. R., Said, J., . . . Belldegrun, A. S. (2003). Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. Journal of Urology, 169(6), 2076-2083. https://doi.org/10.1097/01.ju.0000066130.27119.1c

Pantuck, A. J., Zisman, A., Rauch, M. K., & Belldegrun, A. (2000). Incidental renal tumors. Urology, 56(2), 190-196. https://doi.org/10.1016/s0090-4295(00)00655-5

Parwani, A. V., Husain, A. N., Epstein, J. I., Beckwith, J. B., & Argani, P. (2001). Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation. Human Pathology, 32(5), 506-512. https://doi.org/10.1053/hupa.2001.24320

Patard, J. J., Dorey, F. J., Cindolo, L., Ficarra, V., DE la Taille, A., Tostain, J., . . . Pantuck, A. J. (2004a). Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. Journal of Urology, 172(6), 2167-2171. https://doi.org/10.1097/01.ju.0000141137.61330.4d

Patard, J. J., Leray, E., Cindolo, L., Ficarra, V., Rodriguez, A., De La Taille, A., . . . Lobel, B. (2004b). Multi-institutional validation of a symptom based classification for renal cell carcinoma. Journal of Urology, 172(3), 858-862. https://doi.org/10.1097/01.ju.0000135837.64840.55

Patard, J. J., Leray, E., Rioux-Leclercq, N., Cindolo, L., Ficarra, V., Zisman, A., . . . Pantuck, A. J. (2005). Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. Journal of Clinical Oncology, 23(12), 2763-2771. https://doi.org/10.1200/jco.2005.07.055

Patard, J. J., Rodriguez, A., Rioux-Leclercq, N., Guillé, F., & Lobel, B. (2002). Prognostic significance of the mode of detection in renal tumours. BJU International, 90(4), 358-363. https://doi.org/10.1046/j.1464-410x.2002.02910.x

Permpongkosol, S., Chan, D. Y., Link, R. E., Jarrett, T. W., & Kavoussi, L. R. (2005). Laparoscopic radical nephrectomy: long-term outcomes. Journal of Endourology, 19(6), 628-633. https://doi.org/10.1089/end.2005.19.628

Pischon, T., Lahmann, P. H., Boeing, H., Tjønneland, A., Halkjær, J., Overvad, K., . . . Riboli, E. (2006). Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 118(3), 728-738. https://doi.org/10.1002/ijc.21398

Pongracz, N., Zimmerman, R., & Kotz, R. (1988). Orthopaedic management of bony metastases of renal cancer. Seminars in Surgical Oncology, 4(2), 139-142.

Portis, A. J., Yan, Y., Landman, J., Chen, C., Barrett, P. H., Fentie, D. D., . . . Clayman, R. V. (2002). Long-term followup after laparoscopic radical nephrectomy. Journal of Urology, 167(3), 1257-1262.

Reichel, L. M., Pohar, S., Heiner, J., Buzaianu, E. M., & Damron, T. A. (2007). Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clinical Orthopaedics and Related Research, 459(459), 133-138. https://doi.org/10.1097/BLO.0b013e3180616594

Rendon, R. A., Kachura, J. R., Sweet, J. M., Gertner, M. R., Sherar, M. D., Robinette, M., . . . Jewett, M. A. S. (2002). The uncertainty of radio frequency treatment of renal cell carcinoma: Findings at immediate and delayed nephrectomy. Journal of Urology, 167(4), 1587-1592.

Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., . . . Motzer, R. J. (2011). Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute, 103(9), 763-773.

Rini, B. I., Halabi, S., Rosenberg, J., Stadler, W. M., Vaena, D. A., Atkins, J. N., . . . Small, E. J. (2009). Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. Journal of Clinical Oncology, 27(18S), LBA5019.

Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S. S., . . . Small, E. J. (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. Journal of Clinical Oncology, 26(33), 5422-5428. https://doi.org/10.1200/JCO.2008.16.9847

Robson, C. J., Churchill, B. M., & Anderson, W. (1969). The results of radical nephrectomy for renal cell carcinoma. Journal of Urology, 101(3), 297-301. https://doi.org/10.1016/s0022-5347(17)62331-0

Roy, C., Buy, X., & el Ghali, S. (2003). Imaging in Renal Cell Cancer. EAU Updates Series, 1, 209-214.

Salama, M. E., Peralta-Venturina, M., Guru, K., Peterson, E., Stricker, H., Javidan, J., . . . Amin, M. (2003). pT1 substaging in renal cell carcinoma: Validation of the 2002 TNM staging modification of renal tumors. Modern Pathology, 16(1), 168A-168A.

Sandock, D. S., Seftel, A. D., & Resnick, M. I. (1995). A new protocol for the followup of renal cell carcinoma based on pathological stage. Journal of Urology, 154(1), 28-31.

Sandock, D. S., Seftel, A. D., & Resnick, M. I. (1997). Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology, 49(1), 28-31. https://doi.org/10.1016/S0090-4295(96)00388-3

Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., . . . Schmidinger, H. (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 26(32), 5204-5212. https://doi.org/10.1200/JCO.2007.15.6331

Schwandt, A., Wood, L. S., Rini, B., & Dreicer, R. (2009). Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. OncoTargets and Therapy, 2, 51-61. https://doi.org/10.2147/ott.s4052

Sheth, S., Scatarige, J. C., Horton, K. M., Corl, F. M., & Fishman, E. K. (2001). Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. Radiographics, 21 Spec No, S237-254. https://doi.org/10.1148/radiographics.21.suppl_1.g01oc18s237

Shvarts, O., Tsui, K. H., Smith, R. B., Kernion, J. B., & Belldegrun, A. (2000). Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma. Journal of Urology, 164(4), 1160-1163.

Sobin, L. H., & Wittekind, C. H. (red.). (2002). TNM - Classification of malignant tumours (6. utg.). New York: Wiley.

SSB. (27.05.2005). II Svulster i alt (C00-D48) 2005. ICD-10 Dødsårsak etter detaljert internasjonal liste. [nettdokument]. Oslo: Statistisk sentralbyrå. Hentet 2008, fra http://www.ssb.no/emner/03/01/10/dodsarsak/kap-ii-c00-d48.html

Stadler, W. M., Figlin, R. A., McDermott, D. F., Dutcher, J. P., Knox, J. J., Miller, W. H., Jr., . . . Arccs Study Investigators. (2010). Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, 116(5), 1272-1280. https://doi.org/10.1002/cncr.24864

Staehler, G., & Brkovic, D. (2000). The role of radical surgery for renal cell carcinoma with extension into the vena cava. Journal of Urology, 163(6), 1671-1675. https://doi.org/10.1016/S0022-5347(05)67517-9

Stephenson, A. J., Hakimi, A. A., Snyder, M. E., & Russo, P. (2004). Complications of radical and partial nephrectomy in a large contemporary cohort. Journal of Urology, 171(1), 130-134. https://doi.org/10.1097/01.ju.0000101281.04634.13

Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., . . . Hawkins, R. E. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology, 28(6), 1061-1068. https://doi.org/10.1200/JCO.2009.23.9764

Stewart, J. H., Buccianti, G., Agodoa, L., Gellert, R., McCredie, M. R., Lowenfels, A. B., . . . Maisonneuve, P. (2003). Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. Journal of the American Society of Nephrology, 14(1), 197-207. https://doi.org/10.1097/01.asn.0000039608.81046.81

Storkel, S., Eble, J. N., Adlakha, K., Amin, M., Blute, M. L., Bostwick, D. G., . . . Iczkowski, K. (1997). Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80(5), 987-989.

Svedman, C., Karlsson, K., Rutkowska, E., Sandström, P., Blomgren, H., Lax, I., & Wersall, P. (2008). Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncologica, 47(8), 1578-1583. https://doi.org/10.1080/02841860802123196

Svedman, C., Sandstrom, P., Pisa, P., Blomgren, H., Lax, I., Kalkner, K. M., . . . Wersall, P. (2006). A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncologica, 45(7), 870-875. https://doi.org/10.1080/02841860600954875

Swanson, D. A. (2004). Surgery for metastases of renal cell carcinoma. Scandinavian Journal of Surgery, 93(2), 150-155. https://doi.org/10.1177/145749690409300211

Talamini, R., Baron, A. E., Barra, S., Bidoli, E., La Vecchia, C., Negri, E., . . . Franceschi, S. (1990). A case-control study of risk factor for renal cell cancer in northern Italy. Cancer Causes and Control, 1(2), 125-131. https://doi.org/10.1007/BF00053163

Terrone, C., Cracco, C., Porpiglia, F., Bollito, E., Scoffone, C., Poggio, M., . . . Rossetti, S. R. (2006). Reassessing the current TNM lymph node staging for renal cell carcinoma. European Urology, 49(2), 324-331. https://doi.org/10.1016/j.eururo.2005.11.014

Thomas, A. A., Rini, B. I., Stephenson, A. J., Garcia, J. A., Fergany, A., Krishnamurthi, V., . . . Campbell, S. C. (2009). Surgical resection of renal cell carcinoma after targeted therapy. Journal of Urology, 182(3), 881-886. https://doi.org/10.1016/j.juro.2009.05.014

Thompson, R. H., Leibovich, B. C., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., . . . Blute, M. L. (2005a). Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? Journal of Urology, 173(3), 918-921.

Thompson, R. H., Leibovich, B. C., Cheville, J. C., Webster, W. S., Lohse, C. M., Kwon, E. D., . . . Blute, M. L. (2005b). Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? Journal of Urology, 174(4 Pt 1), 1218-1221.

Thoroddsen, A., Gudbjartsson, T., Jonsson, E., Gislason, T., & Einarsson, G. V. (2003). Operative mortality after nephrectomy for renal cell carcinoma. Scandinavian Journal of Urology and Nephrology, 37(6), 507-511. https://doi.org/10.1080/00365590310015732

Toro, J. R., Glenn, G., Duray, P., Darling, T., Weirich, G., Zbar, B., . . . Turner, M. L. (1999). Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Archives of Dermatology, 135(10), 1195-1202. https://doi.org/10.1001/archderm.135.10.1195

Tsui, K. H., Shvarts, O., Smith, R. B., Figlin, R., de Kernion, J. B., & Belldegrun, A. (2000a). Renal cell carcinoma: prognostic significance of incidentally detected tumors. Journal of Urology, 163(2), 426-430. https://doi.org/10.1016/s0022-5347(05)67892-5

Tsui, K. H., Shvarts, O., Smith, R. B., Figlin, R. A., deKernion, J. B., & Belldegrun, A. (2000b). Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. Journal of Urology, 163(4), 1090-1095; quiz 1295. https://doi.org/10.1016/s0022-5347(05)67699-9

Ueda, T., Tobe, T., Yamamoto, S., Motoori, K., Murakami, Y., Igarashi, T., & Ito, H. (2004). Selective intra-arterial 3-dimensional computed tomography angiography for preoperative evaluation of nephron-sparing surgery. Journal of Computer Assisted Tomography, 28(4), 496-504. https://doi.org/10.1097/00004728-200407000-00010

Uzzo, R. G., & Novick, A. C. (2001). Nephron sparing surgery for renal tumors: indications, techniques and outcomes. Journal of Urology, 166(1), 6-18.

Vaishampayan, U. N., Do, H., Hussain, M., & Schwartz, K. (2003). Racial disparity in incidence patterns and outcome of kidney cancer. Urology, 62(6), 1012-1017. https://doi.org/10.1016/j.urology.2003.07.010

van der Poel, H. G., Roukema, J. A., Horenblas, S., van Geel, A. N., & Debruyne, F. M. (1999). Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. European Urology, 35(3), 197-203. https://doi.org/10.1159/000019849

Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., . . . Sylvester, R. (2007). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European Urology, 51(6), 1606-1615. https://doi.org/10.1016/j.eururo.2006.11.013

Varkarakis, I. M., Allaf, M. E., Inagaki, T., Bhayani, S. B., Chan, D. Y., Su, L. M., . . . Solomon, S. B. (2005). Percutaneous radio frequency ablation of renal masses: results at a 2-year mean followup. Journal of Urology, 174(2), 456-460; discussion 460. https://doi.org/10.1097/01.ju.0000165655.91152.c5

von Knobloch, R., Seseke, F., Riedmiller, H., Gröne, H. J., Walthers, E. M., & Kälble, T. (1999). Radical nephrectomy for renal cell carcinoma: Is adrenalectomy necessary? European Urology, 36(4), 303-308. https://doi.org/10.1159/000020009

Watanabe, K., Ikado, S., Hirabayashi, N., Ogawa, A., Tomita, Y., & Wajiki, M. (1992). [Results of curative or non-curative nephrectomy for renal cell carcinoma invading adjacent organs]. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology, 83(8), 1238-1243. https://doi.org/10.5980/jpnjurol1989.83.1238

Wersall, P. J., Blomgren, H., Lax, I., Kalkner, K. M., Linder, C., Lundell, G., . . . Svedman, C. (2005). Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiotherapy and Oncology, 77(1), 88-95. https://doi.org/10.1016/j.radonc.2005.03.022

Wersall, P. J., Blomgren, H., Pisa, P., Lax, I., Kalkner, K. M., & Svedman, C. (2006). Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncologica, 45(4), 493-497. https://doi.org/10.1080/02841860600604611

Whang, M., O'Toole, K., Bixon, R., Brunetti, J., Ikeguchi, E., Olsson, C. A., . . . Benson, M. C. (1995). The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. Journal of Urology, 154(3), 968-970; discussion 970-961.

Wille, A. H., Roigas, J., Deger, S., Tullmann, M., Turk, I., & Loening, S. A. (2004). Laparoscopic radical nephrectomy: techniques, results and oncological outcome in 125 consecutive cases. European Urology, 45(4), 483-488; discussion 488-489. https://doi.org/10.1016/j.eururo.2003.10.019

Wilson, D., Hiller, L., Gray, L., Grainger, M., Stirling, A., & James, N. (2003). The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clinical Oncology (Royal College of Radiologists), 15(7), 400-407. https://doi.org/10.1016/s0936-6555(03)00164-x

Wood, C. G., & Margulis, V. (2009). Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer, 115(10 Suppl), 2355-2360. https://doi.org/10.1002/cncr.24240

Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., . . . Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine, 349(5), 427-434. https://doi.org/10.1056/NEJMoa021491

Yang, X. J., Tan, M. H., Kim, H. L., Ditlev, J. A., Betten, M. W., Png, C. E., . . . Teh, B. T. (2005). A molecular classification of papillary renal cell carcinoma. Cancer Research, 65(13), 5628-5637. https://doi.org/10.1158/0008-5472.CAN-05-0533

Yokoyama, H., & Tanaka, M. (2005). Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy? BJU International, 95(4), 526-529. https://doi.org/10.1111/j.1464-410X.2005.05332.x

Zama, I. N., Hutson, T. E., Elson, P., Cleary, J. M., Choueiri, T. K., Heng, D. Y., . . . Rini, B. I. (2010). Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer, 116(23), 5400-5406. https://doi.org/10.1002/cncr.25583

Zbar, B., Glenn, G., Lubensky, I., Choyke, P., Walther, M. M., Magnusson, G., . . . Hurley, K. (1995). Hereditary papillary renal cell carcinoma: clinical studies in 10 families. Journal of Urology, 153(3 Pt 2), 907-912.

Zhao, H., Ljungberg, B., Grankvist, K., Rasmuson, T., Tibshirani, R., & Brooks, J. D. (2006). Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Medicine, 3(1), e13. https://doi.org/10.1371/journal.pmed.0030013

Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., . . . Belldegrun, A. S. (2001). Improved prognostication of renal cell carcinoma using an integrated staging system. Journal of Clinical Oncology, 19(6), 1649-1657. https://doi.org/10.1200/Jco.2001.19.6.1649

Zisman, A., Wieder, J. A., Pantuck, A. J., Chao, D. H., Dorey, F., Said, J. W., . . . Belldegrun, A. S. (2003). Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. Journal of Urology, 169(3), 909-916. https://doi.org/10.1097/01.ju.0000045706.35470.1e